Clinical trials: Cystic Fibrosis, Pulmonary
Platelet Levels and Mean Platelet Volume in Patients With CF
Platelets in Cystic Fibrosis Lung Inflammation
Cystic fibrosis (CF) is a chronic multiorgan disorder caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene.
- Trial name
- NCT05339724
- Testing
- platelet count and mean platelet volume are obtained from whole blood count
- Where
- Turkey (Türkiye)
- Volunteers
- 53 people
- Sponsor
- Mersin Training and Research Hospital
Pain, Cystic Fibrosis
Pain in Patients With Cystic Fibrosis in Rouen University Hospital
Objectif Principal To evaluate the intensity and frequency of pain episodes in patients with cystic fibrosis followed at the cystic fibrosis center of Rouen University Hospital, Normandy, France.
- Trial name
- MUCODOL (NCT04561973)
- Testing
- numerical rating scale
- Where
- France
- Volunteers
- 109 people
- Sponsor
- University Hospital, Rouen
Cystic Fibrosis
GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis
This is a Phase IIa, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate GLPG2737 administered orally b.i.d.
- Trial name
- PELICAN (NCT03474042)
- Testing
- GLPG2737
- Where
- 9 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Lakefront Biotherapeutics NV
Cystic Fibrosis
Hydroxychloroquine in Cystic Fibrosis
Study levels of inflammatory mediators in induced sputum of patients with cystic fibrosis before and after a 4 week course of oral hydroxychloroquine.
- Trial name
- NCT00311883
- Testing
- hydroxychloroquine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vanderbilt University
Cystic Fibrosis
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older
The study evaluates the long-term safety, tolerability, efficacy, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in participants with cystic fibrosis (CF).
- Trial name
- NCT04183790
- Testing
- ELX/TEZ/IVA, IVA
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 64 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis, Healthy
Multiple Breath Nitrogen Washout in Healthy and Cystic Fibrosis Adults
This study compares the lung clearance index (LCI) in cystic fibrosis and healthy adults obtained with two different multiple breath nitrogen washout (MBWN2) devices.
- Trial name
- NCT02368080
- Testing
- Comparison of two MBWN2 devices : "EasyOne Pro Lab" versus "Exhalyzer D"
- Where
- Belgium
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Cystic Fibrosis
The Use of Breath Volatile Organic Compounds in Early Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis
This is a single-centre, prospective observational cohort study assessing the potential utility of the Owlstone Medical "Breath Biopsy" in early diagnosis of pulmonary infections in patients with cystic fibrosis (CF).
- Trial name
- NCT05944367
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Cystic Fibrosis
Effectiveness of Pulmozyme in Infants With Cystic Fibrosis
This is a study to find out whether Pulmozyme is effective for clearing mucus from the airways of children with cystic fibrosis less than 3 ½ years of age.
- Trial name
- NCT00179998
- Testing
- Recombinant Human DNase (Pulmozyme)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Nationwide Children's Hospital
Exocrine Pancreatic Insufficiency
Phase 1 Study to Assess Safety and Efficacy of ANG003
Randomized, parallel, active-treatment Phase 1 study of a single dose of orally administered ANG003 with a test meal in adult subjects with cystic fibrosis-related exocrine pancreatic insufficiency.
- Trial name
- NCT06052293
- Testing
- ANG003
- Where
- 20 sites in United States
- Volunteers
- 57 people
- Sponsor
- Anagram Therapeutics, Inc.
Cystic Fibrosis
Effects of an Early Rehabilitation Program During Hospitalization in Patients With Cystic Fibrosis
Studies demonstrate that exercise increases the maximal oxygen uptake, peak oxygen consumption, reduce effort-induced lactic acid production, and increase skeletal muscle oxidative capacity, as well as psychological aspects such…
- Trial name
- NCT03100214
- Testing
- Exercise, Control
- Where
- Brazil
- Volunteers
- 34 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Cystic Fibrosis, Glucose Metabolism Disorders
The Relationship Between Diet and Glycemic Response and Inflammatory Markers in Children With Cystic Fibrosis
The aim of this study is to determine the relationship between diets of children with cystic fibrosis and glycemic responses and some inflammatory markers.
- Trial name
- NCT05748444
- Where
- Turkey (Türkiye)
- Volunteers
- 24 people
- Sponsor
- büşra başpınar
Cystic Fibrosis
Evaluation of a Behavioural Intervention Using App Technology in CF
Cystic Fibrosis (CF) is a lifelong condition which causes the lungs and digestive system to become clogged with thick, sticky mucus. This leads to recurrent chest infections and reduced nutrient absorption from food.
- Trial name
- EAT-CF (NCT03782909)
- Testing
- Behaviour change intervention
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Cystic Fibrosis
Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis
Adult cystic fibrosis (CF) patients admitted with an acute infection complicated by acid-base disturbance and decreased ventilation will be studied.
- Trial name
- NCT00163852
- Testing
- Normal saline IV, salt tablets
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayside Health
Cystic Fibrosis
Early Assessment of Respiratory Function, Inflammation and Bronchial Reshuffle Among Newborns Screened for Cystic Fibrosis
The main objective of this study is to show that there is a concordance between lung disease at 13 months and the existing 9 weeks in newborn babies with cystic fibrosis asymptomatically.
- Trial name
- NCT02883816
- Testing
- assessment of lung function
- Where
- France
- Volunteers
- 52 people
- Sponsor
- University Hospital, Montpellier
Cystic Fibrosis
Phase I Study of the Third Generation Adenovirus H5.001CBCFTR in Patients With Cystic Fibrosis
OBJECTIVES: I. Assess the safety and feasibility of gene transfer with the third generation adenovirus H5.001CBCFTR in patients with cystic fibrosis.
- Trial name
- NCT00004287
- Testing
- H5.001CBCFTR
- Volunteers
- 14 people
- Sponsor
- National Center for Research Resources (NCRR)
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa
Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection
A phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 administered in subjects with non-cystic fibrosis bronchiectasis and chronic…
- Conditions
- Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
- Trial name
- Tailwind (NCT05616221)
- Testing
- AP-PA02
- Where
- 23 sites in United States
- Volunteers
- 48 people
- Sponsor
- Armata Pharmaceuticals, Inc.
Cystic Fibrosis
Oral Docosahexanoic Acid Supplementation in Cystic Fibrosis
Oral supplementation of patients affected by cystic fibrosis with docosahexanoic acid (DHA) will result in normalization of the known fatty acid derangements in these patients and will diminish the production of proinflammatory…
- Trial name
- NCT00924547
- Testing
- Docosahexanoic Acid Supplement
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Vanderbilt University
Cystic Fibrosis
Self Drainage in Pediatric Cystic Fibrosis Patients
In the current study, we designed a cross-over, open label, randomized controlled clinical trial that aim to investigate the superiority of physical exercise coupled with self drainage to a chest physiotherapy in stable cystic…
- Trial name
- GYM-MUCO (NCT01509235)
- Testing
- Chest physiotherapy
- Volunteers
- 34 people
- Sponsor
- Hospices Civils de Lyon
Cystic Fibrosis, Nontuberculous Mycobacterium Infection
Healthcare-associated Links in Transmission of Nontuberculous Mycobacteria in Cystic Fibrosis
Sources of NTM infection and modes of transmission among CF patients are poorly understood. Healthcare-associated transmission of NTM among CF patients has been suspected and is of growing concern for CF Centers.
- Trial name
- HALTNTM (NCT04024423)
- Testing
- Epidemiologic investigation
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Jewish Health
Cystic Fibrosis
Small Circulating RNA as Molecular Markers of Lung Disease in Cystic Fibrosis
The aim of our study is to assess miRNAs expression profiles in the circuling blood of patients with cystic fibrosis and highlight "signatures" that could reflect the pulmonary status of patients
- Trial name
- MIRDIAMUCO (NCT02992080)
- Testing
- miRNAs isolation from blood samples of patients and control
- Where
- 2 sites in France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier